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Cytokines, growth factors, and other locally produced mediators play key roles in the 
regulation of disease progression. During liver fibrosis, these mediators orchestrate the 
balance between pro- and antifibrotic activities as exerted by the hepatic cells. Two 
important players in this respect are the profibrotic mediator platelet-derived growth 
factor BB (PDGF-BB) and the antifibrotic cytokine interferon gamma (IFNγ). PDGF-BB, 
produced by many resident and infiltrating cells, causes extensive proliferation, migra-
tion, and contraction of hepatic stellate cells (HSCs) and myofibroblasts. These cells 
are the extracellular matrix-producing hepatic cells and they highly express the PDGFβ 
receptor. On the other hand, IFNγ is produced by natural killer cells in fibrotic livers 
and is endowed with proinflammatory, antiviral, and antifibrotic activities. This cytokine 
attracted much attention as a possible therapeutic compound in fibrosis. However, 
clinical trials yielded disappointing results because of low efficacy and adverse effects, 
most likely related to the dual role of IFNγ in fibrosis. In our studies, we targeted the 
antifibrotic IFNγ to the liver myofibroblasts. For that, we altered the cell binding properties 
of IFNγ, by delivery of the IFNγ-nuclear localization sequence to the highly expressed 
PDGFβ receptor using a PDGFβ receptor recognizing peptide, thereby creating a con-
struct referred to as “Fibroferon” (i.e., fibroblast-targeted interferon γ). In recent years, 
we demonstrated that HSC-specific delivery of IFNγ increased its antifibrotic potency 
and improved its general safety profile in vivo, making Fibroferon highly suitable for the 
treatment of (fibrotic) diseases associated with elevated PDGFβ receptor expression. 
The present review summarizes the knowledge on these two key mediators, PDGF-BB 
and IFNγ, and outlines how we used this knowledge to create the cell-specific antifibrotic 
compound Fibroferon containing parts of both of these mediators.
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introduction
Nowadays the most prevalent causes of chronic injury to the liver 
are chronic hepatitis B and C viral (HBV and HCV, respectively) 
infections, alcohol abuse, and metabolic problems related to 
obesity. Irrespective of the etiology of the disease, all types of 
chronic damage can finally lead to the induction of a common 
pathological response in the liver. In this common pathological 
response, the same cells and mediators play a role in the progres-
sion from chronic injury to fibrosis, cirrhosis, and eventually to 
tumor formation. At the moment, hepatocellular carcinoma is 
among the top three of most lethal carcinomas and its incidence 
is still increasing (1, 2).
Fibrogenesis is characterized by excessive fibrotic matrix 
deposition and by activation of macrophages and myofibroblasts. 
Within the liver, the major pool of matrix-producing myofibro-
blasts originates from activated and transformed hepatic stellate 
cells (HSCs), although other fibroblast sources such as the portal 
fibroblast or fibrocytes also have been identified (3–5). Clearly 
not only myofibroblasts and resident macrophages (Kupffer cells) 
are involved, but all other resident cell types contribute each in 
their own way to the fibrotic pathology. Additionally, infiltrating 
immune cells, both of the innate and acquired immune system, 
such as B cells, T cells, natural killer (NK) cells, NKT cells, neutro-
phils, and monocytes contribute to the disease progression. Their 
specific roles in the disease are becoming more and more clear 
(4, 6, 7). Although multiple cells are involved in hepatic fibrosis, 
crucial players are the fibroblasts, i.e., in the liver the activated 
HSCs and myofibroblasts, and macrophages, i.e., the Kupffer 
cells together with infiltrated monocytes. The fibroblasts are con-
sidered the master producers of all the fibrotic matrix proteins, 
whereas the macrophages are the master regulators (4, 5, 8).
Fibroblasts and macrophages communicate with each other 
via production and release of various growth factors, cytokines, 
and chemokines. The two most prominent profibrotic growth 
factors are platelet-derived growth factor BB (PDGF-BB) and 
transforming growth factor beta (TGFβ). While PDGF-BB 
stimulates fibroblast proliferation and migration, TGFβ is more 
involved in activation, transformation, and matrix production. 
In our studies, we chose the PDGFβ receptor (PDGFβR) as our 
target receptor for the delivery of antifibrotic compounds (9). 
The PDGFβR was preferred since the TGFβ receptor was not 
only expressed on HSCs and myofibroblasts but also hepatocytes 
and macrophages express this receptor (10–12). Next to the 
high production of profibrotic factors in diseased livers, various 
antifibrotic factors are produced and released as well (13). One of 
the major antifibrotic factors is interferon gamma (IFNγ). This 
cytokine is excreted by infiltrating T cells and NK(T) cells (6, 14). 
However, as disease progression continues, the antifibrotic factors 
cannot effectively counterbalance all profibrotic stimuli, leading 
to disturbance of the homeostatic balance and thus worsening of 
the disease.
In this review, we will give an overview of the characteristics 
and pathological roles of two mediators in fibrosis, i.e., PDGF 
and IFNγ, and summarize their receptor expressions and coun-
terbalancing activities in various cell types. After that, recent 
studies on the structure, the receptor interaction, the in vitro and 
in vivo characteristics of the cell-specific therapeutic compound 
Fibroferon (previously called BipPB-PEG-IFNγ mimetic, mimγ-
BipPB, or BOT191), which contains the most useful parts of both 
these abovementioned mediators, are summarized.
Platelet-Derived Growth Factor
Platelet-derived growth factor, one of the first growth factors 
characterized, was discovered in the early 1970s as a key media-
tor involved in vascular pathologies such as atherosclerosis (15). 
Studies at that time proved that this growth factor, released from 
platelets, promoted vascular smooth muscle cell migration and 
proliferation. Later on, it became clear that PDGF was a potent 
mitogen for all mesenchymal cells, including fibroblasts and 
myofibroblasts. In later decades, PDGF was also identified as the 
most potent mitogen for HSCs in fibrotic livers (16). The distribu-
tion of the PDGF receptor correlated closely with the localization 
of activated mesenchymal cells predominantly present in collagen 
lesions within the liver (17).
Platelet-derived growth factor belongs to the large cysteine-
knot superfamily. This family is characterized by the presence 
of eight conserved cysteine residues, forming a typical cysteine-
knot structure. Within this large family, PDGF is structurally and 
functionally mostly related to the vascular endothelial growth 
factor (VEGF) family. The structure of the PDGF-family is highly 
conserved throughout the animal species (18, 19). Four different 
chains of PDGF-molecules are known: the traditional A- and 
B-chains and the more recently discovered C- and D-chains. The 
PDGF molecule is present in a dimeric form, and four homodi-
meric (AA, BB, CC, and DD) forms and one heterodimeric (AB) 
form are described. PDGF-A (211 aa, 24 kDa) and PDGF-B (241 
aa, 27 kDa) are each other’s paralogs. Both proteins are processed 
mainly intracellularly and secreted in the dimeric active form. 
On the other hand, PDGF-C (345 aa, 39 kDa) and PDGF-D (370 
aa, 43 kDa), also each other’s paralogs, are secreted in a dimeric 
latent form. These PDGF isoforms contain a so-called CUB 
(Complement C1r/C1s, Uegf, Bmp1) domain at the N-terminal 
region of these proteins. This CUB domain, mainly found in 
developmentally regulated extracellular and plasma membrane-
associated proteins, causes retention of PDGF-CC and -DD in the 
extracellular matrix. For interaction with the PDGFR, extracel-
lular activation of the C- and D-chain is necessary and it requires 
proteolytic cleavage of the CUB-domain by tissue plasminogen 
activator or urokinase plasminogen activator, respectively (18, 
20). All five dimeric PDGF-forms can be found in the extracel-
lular space but also in intracellular compartments, such as the 
endoplasmic reticulum and Golgi. There are even reports that 
state that the C-chain can be present in the nucleus (21).
Platelet-derived growth factor exerts its effects via binding to 
one of the two structurally related PDGF receptors, the PDGF 
alpha receptor (PDGFαR; Mw =  123  kDa) and beta receptor 
(PDGFβR; Mw  =  124  kDa) that both belong to the class III 
receptor tyrosine kinases. Similar to the growth factor itself, also 
the receptor exists in homo (αα and ββ) and hetero (αβ) dimeric 
forms, all containing an extracellular part to which a particular 
PDGF-isoform binds and an intracellular signaling part. PDGF-A 
and C chains bind to the α-receptor, while B and D chains bind 
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to the β-receptor. Both receptors are predominantly expressed 
on the cell membrane with minor expression in the lysosomes 
and even nucleus is reported (17, 19). In addition, PDGFαR was 
detected as a soluble receptor in the extracellular space (22).
Biological effects
Platelet-derived growth factor has a clear role during embryonic 
development (18), but after that, in normal healthy tissues the 
activity and expression of the PDGF system is very limited. 
During pathological conditions, however, the PDGF system is 
activated again and diseases that are associated with overactiv-
ity of the PDGF system can be divided in three groups: tumors, 
vascular diseases, and fibrotic diseases. In fibrotic livers, several 
inflammatory and fibrotic mediators, such as interleukin-1β, 
tumor necrosis factor alpha (TNFα), TGFβ, and fibroblast growth 
factor (FGF), are released that can increase PDGF and its receptor 
expression. In addition, bacterial endotoxin (lipopolysaccharide), 
which is released in the serum after intestinal leakage and associ-
ated with liver fibrosis induction, can upregulate PDGFR expres-
sions in the liver (23). The upregulation of the PDGFβ receptor in 
human cirrhotic livers was previously shown by Bansal et al. (24).
Various isoforms of PDGF are reported to be present in the 
fibrotic liver, and all these isoforms have mitogenic and chem-
oattractive effects on mesenchymal cells. PDGF-BB is the major 
stimulus for mesenchymal cell proliferation, and the PDGFβ 
receptor is primarily involved in this cellular effect of PDGF. 
Also, activation of the β-receptor stimulates chemotaxis, whereas 
activation of the α-receptor is associated with either stimulation 
or inhibition of chemotaxis, depending on the mesenchymal 
cell type. PDGF is known for its effects on intracellular actin 
reorganization resulting in stimulated cell migration, chemotaxis, 
and contraction. There is, however, a difference between both 
PDGF receptors regarding their effects on the actin filament 
system. Whereas both receptors stimulate edge ruffling and loss 
of stress fibers, only the β-receptor mediates the formation of 
circular actin structures on the dorsal surface of the cell. Gu et al. 
nicely showed that these circular structures are involved in rapid 
recruitment, internalization, and membrane relocation of surface 
integrins, and in this way, these circular structures may serve as 
indicators of cellular transition from static to motile states (25). 
Together with TGFβ, PDGF-BB also induces fibroblast activation 
and differentiation, resulting in induction of α-smooth muscle 
actin (α-SMA) expression in these cells (19, 26). Figure 1 gives an 
overview of the PDGF-BB-producing and PDGF-BB-responsive 
cells and its key functions.
The PDGF isoform that is most prominent in liver fibrosis is 
PDGF-BB (16, 17). PDGF-BB is secreted by both resident and 
infiltrating cells of the liver, such as platelets, infiltrating mono-
cytes and macrophages, activated Kupffer cells (M2-dominant 
type), hepatocytes, cholangiocytes, HSCs, and myofibroblasts, 
and it affects primarily HSCs and myofibroblasts. These latter 
cells display a highly induced PDGFβ receptor expression in mice 
and humans, and this expression can be related to the prolifera-
tive and migratory activities of these fibroblasts in fibrosis. Of 
note, activated HSCs and myofibroblasts produce PDGF-BB and 
thus create an autocrine profibrotic loop without interference of 
other cells.
Although PDGF production increases profoundly during the 
disease and thus local concentrations are high, the amounts present 
in the circulation are generally very low. While concentrations of 
only 17.5 ± 3.1 ng/ml were detectable in whole human blood, the 
amount in plasma was undetectable (27). The low concentrations 
in the circulation were due to a very short plasma half-life of less 
than 2 min and due to a high binding affinity to several proteins in 
plasma and extracellular spaces (27). Examples of PDGF-binding 
proteins are its soluble receptor, α2 macroglobulin, and PDGF-
associated protein (PAP). Additionally, various extracellular 
matrix proteins are able to bind PDGF to form a local storage 
pool. This implies that the biological activities of PDGF can be 
modulated by binding to one of these molecules (28, 29).
PDGF-Receptor expression
Platelet-derived growth factor α-receptor and PDGFβR have over-
lapping, but also distinct, expression patterns and physiological 
roles. Generally, PDGFαR signaling is important in embryonic 
development since it controls gastrulation and the embryonic 
development of several organs such as lung, intestine, skin, testis, 
kidneys, bones, and neuroprotective tissues. Some cell types 
only express the PDGFαR, such as platelets and liver sinusoidal 
endothelial cells. PDGFβR signaling is recognized as an essential 
regulator of early hematopoiesis and blood vessel formation. The 
classical target cells for PDGF, fibroblasts and smooth muscle 
cells, express both α- and β-receptors, although the expression of 
the PDGFβR is generally at a much higher level. In fibrotic livers, 
PDGFβR is mainly expressed on the cell membrane of activated 
and transformed HSCs or myofibroblasts in the collagenous 
fibrotic bands (17, 24, 30). Borkham-Kamphorst et  al. showed 
that the PDGFRs in the endothelium and hepatocytes are more of 
the α-type (30). In addition, PDGFαR was stained outside the area 
of CCl4-induced hepatocellular fibrosis, and they speculated that 
this increased expression could be related to hepatocyte survival. 
Furthermore, they found that the upregulation of PDGFαR was 
accompanied by PDGF-A and PDGF-C staining in regenerative 
hepatocytes after CCl4 intoxication.
How PDGF exactly binds to its receptor is the subject of vari-
ous studies. Insight into this interaction can lead to the genera-
tion of PDGF receptor antagonizing drugs or to drug targeting 
compounds. Already in early 1990s, Clements et  al. identified 
arginine 27 and isoleucine 30 as the PDGF-B chain residues that 
mediate the binding of the growth factor to the β-receptor in rat 
and human cells (31). Binding to the α-receptor requires another 
more cationic part of the molecule (arginine159-lysine160-
lysine161-lysine162), and both in the PDGF-A and -B chain this 
sequence is present (32). More recently, the interaction between 
the growth factor and the receptor was studied in more detail with 
modern techniques like crystallography, partly confirming the 
abovementioned regions in PDGF, but also pointing to additional 
points of interaction with its receptors (33, 34).
PDGF-Receptor Signaling
After binding of PDGF to one of the receptor chains, dimerization 
of the receptor is induced and this receptor dimer is then stabilized 
by the ligand. The subsequent interaction between the cytoplas-
mic domains of the two receptor chains induces phosphorylation 
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of intracellular tyrosines leading to conformational changes in 
the PDGF receptor protein and thus to activation of the kinase 
domains of the receptor. Activation of src-homology-2 (SH2) or 
phosphotyrosine-binding (PTB) domains will lead to activation 
of one of the downstream cytoplasmic pathways. Although more 
pathways are described, activation of the MAPK/ERK pathway, 
the AKT/PKB pathway, and the PKC pathway are the major 
routes (19, 35). The MAPK/ERK pathway is also known as the 
Ras–Raf–MEK–ERK pathway because the GTP-binding protein 
Ras can activate mitogen-activated protein kinases (MAPK) such 
as extracellular signal-regulated kinase (ERK). Phosphorylated 
ERK-1 and -2 form activated ERK dimers and they translocate to 
the nucleus, where they can activate cellular processes linked to 
stimulation of cell proliferation and chemotaxis. Phosphoinositol 
3-kinase can also be recruited to the activated PDGF receptor 
leading to stimulation of cell proliferation and migration via 
the AKT/PKB pathway. AKT, however, regulates multiple other 
biological processes including glycogen metabolism and cell sur-
vival, and it is linked to promotion of tumor growth. Activation of 
the third pathway involves phospholipase C-γ (PLC) recruitment 
after stimulation of the PDGFR. This causes mobilization of cel-
lular Ca2+ storage pools and leads to activation of the intracellular 
signaling molecule protein kinase C (PKC). This route is also 
associated with increased cell growth and motility.
intracellular Routing of PDGF and its Receptor
Much is known about the intracellular signaling and biological 
effects of PDGFR. However, the cellular kinetics of the PDGFR 
itself is less well studied and also the fate of the growth factor and 
its receptor after binding of the ligand at the cell membrane lead-
ing to induction of intracellular signaling is poorly described. It is 
described that the PDGFβR is localized in specialized structures 
of the cell membrane referred to as caveolae (36–38). The mor-
phology of these structures is generated by the protein caveolin 
and they are enriched in glycosphingolipids and cholesterol 
(39). Sorkin et al. showed that induction of the tyrosine kinase 
activity of the PDGFβR promotes ligand-induced internalization 
and subsequently degradation of the ligand–receptor complex in 
endosomal and lysosomal compartments of the cell. They showed 
FiGURe 1 | Overview of PDGF-BB and iFNγ-producing cells and cells that respond to these mediators of fibrogenesis, illustrating the versatility of 
both mediators.
that the receptors began to migrate out of caveolae after 1 h of 
exposure to PDGF and that the internalized PDGFβR retained 
kinase activity and thus could participate in signaling consider-
able time after internalization (36). The receptor can recycle 
back to the cell membrane waiting for its next signal. The fate 
of the growth factor after dissociation from the receptor in the 
endosomes is degradation in the lysosomal compartment, but 
other intracellular routes are possible (40).
interferon Gamma
The involvement of interferons (IFNs) in the defense response 
against viral infections was first described in 1957. Isaacs and 
Lindenmann reported that influenza virus-infected cells produced 
a secreted factor, i.e., interferon, that caused a virus-resistant state 
in previously uninfected cells (41). The biochemical characteriza-
tion of this activity was pursued for a long time without success, 
and it was only in the late 1970s that the interferon protein 
sequence was ascertained (42, 43). Later, it appeared that the 
biological activities of IFNs were much broader, and antifibrotic, 
antitumor, immunoregulatory, and proinflammatory activities 
were also assigned to the IFN family (44).
Interferons, belonging to the interferon/interleukin-10 
cytokine family, can be divided in two groups (type I and II). They 
are classified according to their receptor specificity and sequence 
homology (14). The type I IFNs, also described as viral IFNs, 
include IFNα (of which currently 17 subtypes are described), 
IFNβ, IFNω, and IFNτ. These type I factors are produced by 
almost all cell types. The type II IFNs consist only of IFNγ, which 
shows structurally little to no homology with type I IFN, and 
this protein is also described as immune IFN (45). In contrast 
to these type I IFNs, expression and secretion of IFNγ is not the 
result of the infection itself, but occurs by activated immune cells 
after recognition of infected cells (46). Therefore, although IFNγ 
possesses antiviral activity, it functions primarily as an immune 
modulator responsible for pathogen clearance rather than an 
antiviral compound (47, 48).
Interferon-γ is a non-covalently bound, homodimeric glyco-
protein with subunits consisting of 146 amino acids (17.1 kDa) 
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(49, 50), which are connected in an antiparallel fashion (45). 
Intracellular processing of this cytokine includes intensive glyco-
sylation, giving rise to a mature form of the molecule that exhibits 
a predominant molecular mass of 50  kDa (51). Murine and 
human IFNγ show approximately only 40% sequence homology 
at the protein level (http://www.uniprot.org). The main cell types 
that produce IFNγ upon endogenous or exogenous stimulation 
in the fibrotic liver include T lymphocytes and NK(T) cells, B 
cells, and other antigen-presenting cells (52–58). NK cells were 
shown to be involved in the resolution of fibrosis in both mice 
and humans by stimulating the production of IFNγ, but also via 
killing of activated HSCs (59–61). The production of IFNγ in 
turn increased the number of NK cells (60). Emerging evidence 
suggests that NK cells and IFNγ are very important in the nega-
tive regulation of liver fibrosis (6). This was demonstrated by the 
amelioration of liver fibrosis in vivo, after activation of NK cells by 
poly I:C or treatment of rodents with IFNγ (60, 62–64).
Biological effects
Within the liver, IFNγ exerts a variety of sometimes even oppos-
ing effects. For example, IFNγ is known to be a potent activator 
of macrophages, by stimulating them to kill phagocytosed 
microbes and cancer cells and inducing the production of TNFα 
and interleukin-12 (65). IFNγ induces an inflammatory (“M1”) 
activation state of the hepatic macrophages (comprising resident 
Kupffer cells and infiltrating monocytes and macrophages) (66). 
The proinflammatory factors produced via this route can activate 
the HSC to become a profibrotic myofibroblast. In addition, IFNγ 
induces the expression of both MHC-I and MHC-II in several 
cells (44), promotes the differentiation of T- and B-lymphocytes, 
and activates neutrophils, all contributing to promotion of 
fibrosis. It was also reported that IFNγ inhibits the proliferation 
of vascular endothelial cells (65). On the other hand, IFNγ has 
direct antifibrotic effects when it interacts with HSCs. Increased 
production of IFNγ, as secreted by NK cells in fibrotic livers, is 
accompanied by an increase in TNF-related apoptosis-inducing 
ligand (TRAIL) expression in NK cells, which causes both induc-
tion of apoptosis and cell cycle arrest in HSCs (60, 64, 67). The 
interaction between the stimulatory receptor NKG2D on NK cells 
and its ligand retinoic acid early inducible 1 (RAE1), expressed 
on activated HSCs, leads to killing of activated HSCs by NK cells 
and thus to resolution of fibrosis (60). A summary of cells that 
produce and respond to IFNγ and its main functions is presented 
in Figure 1.
In addition, IFNγ leads to reduced α-SMA, HSC proliferation, 
and collagen levels in fibroblasts (24, 62). IFNγ antagonizes the 
profibrotic activities of TGFβ, most probably by intracellular 
induction of the expression of the antagonistic Smad7. Smad7 
causes impairment of the TGFβ response, via blocking of the 
interaction of the transcription factor Smad3 with the TGFβ 
receptor (68).
iFNγ-Receptor expression
Like many other cytokines, the receptor for IFNγ consists of 
multiple distinct subunits: the α chain (IFNγR1; 54.4  kDa), 
necessary for ligand binding and processing, and the β subunit 
(IFNγR2; 37.8  kDa), needed to induce a biological response 
by triggering the intracellular signal transduction cascade (14, 
69). The complete receptor complex contains two IFNγR1 and 
two IFNγR2 subunits and these four parts associate after ligand 
binding. In more detail, IFNγ binds to one IFNγR1 and induces 
rapid dimerization of two IFNγR1 chains, thereby forming a 
site that is recognized by the extracellular domain of IFNγR2 
(45). The IFNγR2 chain is generally the limiting factor in 
IFNγ responsiveness, as the IFNγR1 chain is usually in excess 
(45, 70). The IFNγR2 chain is constitutively expressed, but its 
expression level is tightly regulated according to the state of 
cellular differentiation or activation. Of note, the binding of 
human and murine IFN to their receptors is strictly species 
specific. They only induce an effect in species-matched cells. 
Moreover, the interaction of IFNγ with its receptor is not 
inhibited by type I IFNs (45).
Interferon-γ R1 and R2 are ubiquitously expressed on the cell 
membrane of virtual all types of cells, but most predominantly 
on cells of the immune system. In particular, macrophages 
are strongly positive for the IFNγR. Within the fibrotic liver, 
expression on infiltrated macrophages and Kupffer cells is high, 
while other cells like HSCs and hepatocytes weakly express the 
receptor (71). Bansal et al. previously showed the ubiquitous and 
increased expression of the IFNγR1 in human cirrhotic livers 
as compared to healthy livers (72). Although expression of the 
IFNγR at the plasma membrane varies widely between tissues 
(200–25,000 sites/cell), no direct correlation between the expres-
sion level and the magnitude of IFN-induced responses in cells 
was found (45).
iFNγ-Receptor Signaling: The Classical Model
In the case of IFNγ, a conformational change in the receptor cyto-
plasmic domain is induced upon binding of IFNγ to the extracel-
lular domains of two IFNγR1 chains. This causes movement of the 
inactive Janus activated kinase 2 (Jak2) from IFNγR2 to IFNγR1 
and subsequent autophosphorylation and activation (73). After 
transphosphorylation and activation of Jak1 by Jak2, the recruit-
ment of signal transducer and activator of transcription 1 alpha 
(Stat1α) is induced by phosphorylation of tyrosine440 residues 
of both IFNγR1 subunits, forming a homodimeric complex of 
pStat1α (69, 74–76). This Stat1 pair dissociates from the receptor 
upon phosphorylation at the tyrosine 701 residue, followed by 
active nuclear translocation via its nuclear localization sequence 
(NLS) (73, 74). In the nucleus, dimeric Stat1α binds to the IFNγ-
activated sequence (GAS element) of the IFNγ-promoter, thereby 
determining specific gene activation of fibrosis-related genes like 
procollagen I and III and TGFβ, but also transcription factors 
like interferon regulatory factor-1 (IRF-1) (77–79). The cellular 
response of IFNγ occurs within 15–30 min after treatment (80). 
Binding of dimeric Stat1α to the GAS element is regarded as 
validation of the classical model of cytokine signaling (81).
To a lesser extent, IFNγ-signaling also produces heterodimeric 
complexes like Stat1:Stat2 and heterotrimeric complexes such 
as Stat1:Stat1:IRF-9 and Stat1:Stat2:IRF-9 (77, 82–84). These 
complexes are able to bind to IFN-stimulated response element 
(ISRE) promoter regions in target genes to regulate transcription 
of, for example, inducible nitric oxide synthase (iNOS), IRF-2, 
and IFNβ (14).
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iFNγ-Receptor Signaling:  
The Non-Canonical Model
Several reasons led to the recognition that the classical model 
of cytokine signaling is an oversimplified model. It was shown 
that upon IFNγ stimulation besides the Jak/Stat pathway, also 
other pathways were activated or interfered with the Jak/Stat 
signaling. Examples include the activation of MAPK, phos-
phoinositide 3-kinase, Ca2+/calmodulin kinase II, and nuclear 
factor-κB (85). Moreover, it was shown in multiple cell lines 
that besides activated Stat, also Jak kinases were involved in the 
epigenetics of gene activation, indicating that Stat1 is not the 
only key player in the IFNγ signaling (86). In addition to this, 
many ligands activate the same Stat transcription factors, but 
have completely different effects in cells, tissues, or organs (87). 
In the classical model of signaling of IFNγ, it is suggested that 
the Stat proteins possess intrinsic NLSs, which are responsible 
for the nuclear translocation of Stat1 and subsequent IFNγ-
related gene activation (88). Of note, in this classical model, the 
internalization of the ligand–receptor complex does not play an 
active role in the signaling process (87). Different to what was 
assumed in the classical model, it appeared that ligand, receptor, 
and activated Jaks and Stats were directly involved in nuclear 
events leading to specific gene activation. Therefore, the non-
canonical model of IFNγ-signaling was developed, which shows 
large resemblance to that of steroid hormone/steroid receptor 
signaling (81).
In this model, IFNγ binds to the extracellular domain of 
the receptor and moves to the cytoplasmic side of the IFNγR1 
domain, after which endocytosis of this complex is induced. The 
movement of Jak2 to the R1 domain results in autoactivation of 
the Jaks. This causes phosphorylation of R1 and eventually the 
recruitment and activation of Stat1α. The complex of IFNγ, the 
IFNγR1, Stat1α, and Jak1 and 2 is actively transported to the 
nucleus, a process which is under the influence of the NLS of 
IFNγ (14, 81, 87). The non-canonical model of IFNγ signaling 
formed the conceptual framework for the development of IFNγ 
mimetics (81).
intracellular Routing of iFNγ and its Receptor
In contrast to the numerous publications on the signal transduc-
tion and biological effects of IFNγ similar to the PDGFβ receptor, 
there are relatively little data available on the trafficking of the 
IFNγ receptor. The interferon receptor has been localized in 
clathrin-coated pits (CCPs), lipid rafts, and caveolae (39).
Clathrin-coated pits are specialized regions in the plasma 
membrane that are engaged in the efficient internalization of 
receptors from the cell surface. It is known that most trans-
membrane receptors are endocytosed via clathrin-dependent 
endocytosis which involves CCPs (89). Both IFNγ and its recep-
tor were shown to be associated with CCPs (90, 91). In general, 
receptors are recruited into CCPs through direct binding of 
their cytoplasmic binding motifs to the adaptor-related protein 
complex 2 (AP-2).
It is suggested that other endocytotic pathways also may par-
ticipate in the endocytosis of the IFNγ receptor (39). Lipid rafts 
are microdomains in the plasma membrane, which are enriched 
in certain lipids, cholesterol, and proteins, caused by redistribu-
tion within the lateral plane of cellular membranes. It is hypoth-
esized that rafts exist in a separate phase that diffuses dynamically 
in a sea of poorly ordered lipids in the plasma membrane. By 
dynamic diffusion, proteins can be included or excluded in these 
rafts (91). The IFNγ receptor was shown to be present in lipid 
rafts. Moreover, the downstream signaling molecules Jak1 and 
2 and Stat1 were also associated with lipid rafts in the plasma 
membrane (92–94). Caveolae are considered a subtype of lipid 
rafts (39). It was shown that IFNγ and its receptor also localize in 
caveolae, albeit to a lesser extent than in CCPs (95).
When the ligand–receptor complex is internalized via endo-
cytosis, it enters a cellular compartment with acidic pH. Within 
this compartment, the ligand dissociates from the receptor. 
Free IFNγ can then be trafficked to the lysosome, where it is 
degraded. In many cells, such as fibroblasts and macrophages, 
the receptor eventually recycles back to the cell surface. In most 
cells, the intracellular pool is approximately two to four times 
larger when compared with the receptors expressed at the cell 
surface (96–100).
Mimetic iFNγ
It was previously shown that the N-terminal side of IFNγ 
plays an important role in the recognition of the extracellular 
domain of its receptor, whereas the C-terminus is involved in 
endocytosis by binding to the membrane proximal region of 
the cytoplasmic part of the IFNγR1 subunit (101). Therefore, 
it is suggested that the N-terminal region of IFNγ is involved 
in species-specific recognition and binding, whereas the 
C-terminal region may be involved in binding of internalized 
IFNγ to the cytoplasmic receptor domain (101). This led to 
the development of a truncated peptide, which contains the 
C-terminal region of IFNγ, namely mimetic IFNγ (IFNγ95–132 AA) 
(101). It appeared that this mimetic peptide possesses similar 
biological activities as its full length equivalent, despite the 
fact that it is not able to bind to the extracellular domain of 
its receptor (102). It was for instance shown that mimetic 
IFNγ possesses IFNγ-agonistic activity without toxicity, such 
as the induction of MHCII expression on macrophages (101). 
Furthermore, mimetic IFNγ displayed antiviral activity in tissue 
cultures and in mice (103). In order to be able to deliver mimetic 
IFNγ into the cytoplasm, the peptide was modified with a single 
N-terminal ε-palmitoyl-lysine residue. This was shown to be 
suitable to allow penetration across the cell plasma membrane 
and subsequent cytoplasmic delivery (87, 104), but the use of 
this palmitoyl residue is unfavorable for in vivo use because it 
induces non-specific uptake in any cell it encounters. Similar to 
IFNγ, mimetic IFNγ forms a complex with IFNγR1, Stat1α, and 
Jak1 and 2 and translocates to the nucleus as directed by its NLS 
(14, 81, 87). Advantages of mimetic proteins in general are their 
versatility, the high biological activity and specificity, and their 
low toxicity (103). There are already several peptide mimetics on 
the market to treat a broad variety of diseases. One example is 
the tripeptide mimetic boceprevir for the treatment of hepatitis 
C viral infections (105). The therapeutic applications of mimetic 
IFN are nowadays explored (106).
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Antifibrotic Compounds
Although in the past decade some progress was made, the 
development of antifibrotic drugs for the treatment of liver 
cirrhosis is still in its infancy. Major steps forward in the treat-
ment of liver diseases were made at the level of eradication of 
the inciting stimulus. The high successes obtained with anti-
HCV drugs that effectively clear the virus and thus reverse the 
chronic pathology also resulted in cases in which regression 
of the fibrosis in the livers of these patients was ascertained 
(107). This contributed to the belief that liver fibrosis even 
in advanced state is reversible and treatable. Parallel to this, 
experimental therapeutic interventions directly aiming at 
fibrogenic key cells and processes emerged (4, 108). In 2005, 
Pinzani et  al. showed an impressive list with all possible 
compounds under (pre)clinical investigation for the treatment 
of liver fibrosis (109). Later on, more reviews with promising 
antifibrotic drugs appeared (110–112). Currently 370 clinical 
trials are listed at http://www.clinicaltrials.gov, illustrating the 
upcoming incidence of clinical trials ongoing in liver cirrhosis, 
and showing that the pharmaceutical industry is interested to 
invest in drugs for the treatment of liver cirrhosis, despite the 
expected long-term trials to assess efficacy in this chronic, slow 
progressing disease. Of note, about 90% of the clinical trials 
are still dealing with diagnostics improvements, treatment of 
cirrhosis-associated complications, or with the application 
and evaluation of direct antiviral agents. This means that only 
a minority of the clinical studies really tests novel antifibrotic 
compounds (108). Remarkably, there are hardly any completed 
or ongoing clinical trials in patients with liver cirrhosis test-
ing compounds that target PDGF and IFNγ pathways. Only 
in 2002, a study was started in which IFNγ1b was tested for 
safety and efficacy in HCV patients with liver fibrosis or cir-
rhosis. However, although IFNγ was well tolerated, the drug 
was abandoned and not approved because of lack of antifibrotic 
activity (113, 114). With regard to intervention at the PDGF 
level, several experimental approaches aiming at PDGF were 
described in literature. Examples include inhibition of the 
PDGF-B chain (115, 116), inhibition of the PDGFβ receptor 
expressions (117, 118), and inhibition of the PDGFβ receptor 
signaling (119, 120). However, none of these compounds were 
found in the clinical trial database on liver fibrosis or cirrhosis.
New targets for direct-acting antifibrotic compounds were 
identified in the past decades due to a better understanding of the 
pathological process at molecular level. This includes the specific 
roles of the different (hepatic) cell types, the mediators involved 
in the communication between these cells and their intracellular 
signaling pathways, and the unravelment of the complex process 
of fibrotic extracellular matrix deposition, during which matrix 
degrading matrix metalloproteinases (MMPs) and inhibitors of 
these metalloproteinases (TIMPs) parallel the enhanced produc-
tion of matrix components. This basic knowledge contributed 
to the generation of various antifibrotic compounds that can be 
tested in patients with liver cirrhosis. One of the current promising 
ongoing clinical trials deals with the application of mesenchymal 
stem cells to treat liver cirrhosis (121). Mesenchymal stem cells 
have shown to have the ability to effectively reduce liver fibrosis 
and improve liver function. The effects are based on various activi-
ties of these mesenchymal stem cells. First, these stem cells can 
differentiate into hepatocytes, allowing the replacement of dam-
aged hepatocytes, and they can promote regeneration of residual 
hepatocytes. In addition, mesenchymal stem cells also affect 
HSCs and possess immunomodulatory properties, all adding to 
their antifibrotic potential. However, some limitations need to be 
considered. Over the past few years, concerns have been raised 
about its long-term effectiveness, the potential tumorigenic risk, 
and the lack of standardized protocols for mesenchymal stem cell 
transplantation.
The development of cell-specific antifibrotic drugs is 
another approach that seems promising (122–124). Fibroferon, 
based on the structure of both PDGF-BB and IFNγ, is one 
of the latest compounds in this context. Fibroferon is an 
IFNγ-derived mimetic peptide that is specifically delivered 
to activated HSCs and myofibroblasts. We used the highly 
upregulated PDGFβR as a target receptor for the HSC/
myofibroblast-directed drug targeting approach in fibrosis. 
We were the first to be able to deliver drugs to HSCs using 
a series of modified proteins, and one of these drug carriers 
was directed at the PDGFβR (9, 125, 126). Nowadays, several 
groups have developed or applied cell-specific proteins to 
HSCs (124, 127–129), recently reviewed by Poelstra et  al. 
(122). In the following paragraphs, we will delineate our 
approach and show, as depicted in Figure 2, how this has led 
to the development of the promising antifibrotic PDGFβR-
targeted interferon, referred to as Fibroferon.
PDGFβ Receptor Recognizing Peptide
We designed a cyclic peptide (pPB) that mimics the binding site 
of PDGF-BB to its endogenous receptor. Similar to PDGF-BB 
itself, the arginine and isoleucine residues and their adjacent 
amino acids represent the PDGFβ receptor binding moieties in 
the pPB peptide (C*SRNLIDC*, where the C* denotes the cycliz-
ing cysteine residues) (31). The peptide was designed in a cyclic 
conformation because earlier observations revealed that cyclic 
peptides have stronger interactions with their receptors and have 
increased stability in plasma as compared to their linear analogs 
(130, 131).
At first, a number of pPB peptides were coupled to human 
serum albumin (HSA) yielding the HSC-specific carrier pPB-
HSA (see Figure 2) (9). The PDGFβ receptor requires a dimeric 
interaction for ligand binding and receptor activation (132) and 
therefore multiple pPB moieties (on average 10 molecules of pPB 
per 1 molecule HSA at different distances from each other) were 
necessary to obtain optimal receptor binding.
It was confirmed in vitro that pPB-HSA bound to the PDGFβ 
receptor on fibroblast cell lines and on primary rat HSCs. This bind-
ing was inhibited by PDGF-BB but not by PDGF-AA. Coupling of 
pPB-peptides to a macromolecule like HSA was necessary for a 
competitive effect with PDGF-BB, since free pPB did not displace 
PDGF-BB from its receptor. PDGFβR-induced effects were not 
found after incubation of fibroblasts with pPB-HSA. Based on 
these observations, it was hypothesized that coupling of pPB to 
FiGURe 2 | Design of constructs directed at the PDGFβ receptor in time, finally leading to the development of Fibroferon. The first PDGFβR-targeted 
product was the carrier pPB-HSA in which several (on average n = 10) groups of pPB were randomly attached to human serum albumin (HSA), in order to allow 
multivalent interaction with the PDGFR. Several other constructs, comprising a therapeutic entity (drug or protein) coupled to this carrier, were subsequently 
developed and tested in vivo. In the final step, the structure was simplified by omitting the albumin protein core and applying low-molecular-weight PEG to couple 
truncated IFNγ to BipPB, to create divalent interaction of truncated IFNγ with the PDGFβR.
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a macromolecule such as HSA enabled a multivalent interaction 
with the PDGFβR, but no receptor activation was induced by 
pPB-based molecules. In vivo, pPB-HSA was shown to accumu-
late in HSCs in fibrotic human, mouse, and rat livers (9); cells 
expressing the highest PDGFβR. These results formed the basis 
for the development of HSC-selective targeting of drugs applying 
pPB-HSA as drug carrier and for example the antifibrotic agents 
IFNγ(133) and 15d-prostaglandin-J2 (134) were evaluated. This is 
particularly relevant for IFNγ, which has a therapeutic application 
in a wide variety of immunological, viral, and neoplastic diseases, 
and where high percentages, up to 100%, of patients suffer from 
general side effects such as headache, malaise, and fever (44). 
A fundamental question is however whether a cytokine can be 
delivered to another target receptor, without losing the biological 
effects elicited by its endogenous receptor.
pPB-Based Delivery of iFNγ to HSCs for the 
Treatment of Liver Fibrosis
We further developed HSC-selective compounds containing the 
cyclic peptide pPB and covalently conjugated this peptide to the 
antifibrotic compound IFNγ (see Figure  2). This led to various 
compounds either with (pPB-PEG-IFNγ and pPB-HSA-PEG-
IFNγ) or without (pPB-IFNγ) polyethylene glycol (PEG) linker in 
between (24, 133). The choice for a distinct PEG-linker was based 
on previous experiments, showing that PEGylation of IFNγ with 
different sizes of PEG-molecules (5, 10, and 20  kDa) improved 
the pharmacokinetic profile, liver uptake, and antifibrotic effects 
of IFNγ, with the smallest PEG molecule as most favorable (72). 
Additionally, improved conformational flexibility of the pPB 
peptide using a PEG spacer allowed improved presentation of pPB 
to the PDGFβ receptor (72). Our conjugates were shown to bind to 
the PDGFβ receptor on fibroblasts and HSCs and inhibited their 
activation in vitro, as shown by a reduction in collagen type I and α-
SMA expression. In addition, the conjugates were shown to inhibit 
PDGF-induced cell proliferation. A remarkable finding in these 
studies was that the specific binding to the PDGFβ receptor and 
subsequent biological effects of the pPB-modified IFNγ-constructs 
was not species-specific anymore in contrast to IFNγ. This was 
demonstrated by the absence of both binding and an antifibrotic 
effect of mouse IFNγ in human cell cultures, whereas mouse IFNγ 
conjugated to pPB did bind to human cells and showed biological 
activity (24, 133). It was therefore proposed that following binding 
to the PDGFβ receptor, the complex was internalized, degraded, 
and IFNγ (or its signaling moiety) was released into the cytoplasm 
leading to IFNγ-mediated effects (135).
The targeted constructs (pPB-PEG-IFNγ, pPB-HSA-PEG-
IFNγ, and pPB-IFNγ) colocalized with desmin-positive PDGFβR-
expressing HSCs in the liver. In addition, they strongly inhibited 
fibrogenesis and induced fibrolysis in a 2-week treatment study 
in 8-week-old CCl4 mice, as demonstrated by attenuated collagen 
type I and α-SMA deposition. Additionally, the balance between 
collagen-degrading MMP-13 and its endogenous inhibitor 
TIMP-1 was shown to be shifted toward a fibrolytic state, charac-
terized by a reduced TIMP-1 expression. This effect was not seen 
in the animals treated with untargeted IFNγ. Furthermore, in 
contrast to untargeted IFNγ, the targeted IFNγ conjugates did not 
induce unwanted IFNγ-related side effects. In these mice treated 
with targeted IFNγ, systemic inflammation, hyperthermia, 
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elevated plasma triglyceride levels, and neurotropic effects, as 
demonstrated by among others a reduced release of proinflam-
matory cytokines (IL-1β), were absent. Moreover, targeted IFNγ 
lowered MHC-II expression in the brain as compared to native 
IFNγ (24, 133), which makes this compound attractive for long-
term treatment.
Redirection of IFNγ to myofibroblasts in the fibrotic liver 
proves to be a promising approach. We pursued this by creating a 
smaller, more simplified construct to facilitate clinical application 
(see Figure 2) (24, 133). This minimized structure combines three 
basic elements, i.e., IFNγ-activity, PEG, and a PDGFβR-binding 
peptide (106). In this truncated IFNγ structure (i.e., mimetic 
IFNγ), the extracellular IFNγ receptor binding sequence was 
removed, yet the NLS accommodating the biological effects of 
IFNγ was retained. In this way, interaction with the ubiquitously 
expressed IFNγ receptor at the membrane of the cells was pre-
vented, leaving only an interaction with the intracellular IFNγR 
(136, 137). This mimetic IFNγ-structure was redirected to the 
PDGFβ receptor by coupling it to PDGFβR-recognizing peptides. 
We also minimized this entity by incorporating only two cyclic 
PDGFβ receptor binding peptides (BipPB) at a specific distinct 
distance from each other to allow dimeric ligand–receptor inter-
action. The PEG linker was minimized to only 2 kDa and BipPB, 
PEG, and mimetic IFNγ were subsequently coupled in a 1:1:1 
ratio, yielding an 8.8 kDa construct (referred to as mimγ-BipPB, 
BOT191, or Fibroferon). Similar to pPB-PEG-IFNγ, Fibroferon 
markedly inhibited both early and advanced CCl4-induced liver 
fibrosis in mice and significantly reduced IFNγ-related side effects 
(106). The advantages of this targeted mimetic IFNγ-conjugate are 
the in vivo stability, the cell selectivity, dissociation of effects, the 
loss of species specificity, the minimal size, and less complexity, 
making it a better-defined product. This all provides Fibroferon 
with clear advantages above the therapeutic use of native IFNγ as 
an antifibrotic compound.
pPB-Based HSC-Selective Drug Carriers  
for the Treatment of Other Diseases
In addition to the demonstrated antifibrotic properties of redi-
rected truncated IFNγ in a mouse liver fibrosis model, antifibrotic 
effects of pPB-PEG-IFNγ were also found in the unilateral 
ureteral obstruction (UUO) mouse model for renal fibrosis. 
In this model, pPB-PEG-IFNγ specifically accumulated in 
PDGFβR-overexpressing interstitial myofibroblasts in the kidney. 
Treatment of mice with pPB-PEG-IFNγ significantly attenuated 
collagen I, fibronectin, and α-SMA mRNA levels and protein 
expression in fibrotic kidneys similar to the liver fibrosis studies. 
Compared to vehicle treatment, pPB-PEG-IFNγ protected the 
tubular morphology, significantly attenuated interstitial T-cell 
infiltration and reduced the formation of lymphatic vessels, 
without affecting the peritubular capillary density. In addition, 
pPB-PEG-IFNγ reduced IFNγ-mediated side effects, as shown by 
reduced MHC-II mRNA expression in the brain (135), which was 
applied as a marker for off-target effects on macrophages.
pPB-HSA-IFNγ was also shown to be effective as antitumor 
agent (138) because the PDGFβ receptor is also upregulated in 
various types of cancer (139, 140). The PDGFβ receptor was 
immunohistochemically shown to be abundantly expressed in 
stromal cells and pericytes of neoplastic human diseases, like 
colorectal, pancreatic, and breast cancer (19). Stromal cells, 
including tumor-associated fibroblasts, endothelial cells, vascular 
pericytes, and infiltrating inflammatory cells, are increasingly 
recognized as key players in the induction of growth and 
progression of tumors (141, 142). Activation and migration 
of fibroblasts and tube formation in endothelial cells induced 
by fibroblasts was inhibited by pPB-HSA-IFNγ, suggesting 
an effect on angiogenic processes. In C26 colon carcinoma 
tumor-bearing mice, pPB-HSA-IFNγ specifically accumulated 
into PDGFβ receptor expressing tumor stromal fibroblasts and 
pericytes and inhibited the tumor growth. Treatment of these 
mice with pPB-HSA-IFNγ was associated with a significant 
inhibition of angiogenesis, as reflected by reduced α-SMA and 
CD31 stainings (138).
Other drugs were also delivered to the PDGFβ receptor using 
the cyclic peptide pPB as a targeting device. For example, the 
anticancer agent doxorubicin was coupled to pPB-HSA via an 
acid-sensitive hydrazine linkage for delivery to the PDGFβ 
receptor on stromal cells. The targeted construct was shown 
to significantly reduce tumor growth with high response rate 
as compared to the untargeted doxorubicin. Therefore, the 
delivery of anticancer drugs to these stromal cells, nurturing 
the neighboring tumor cells, is a novel and maybe promising 
approach to treat cancers effectively (143).
These studies suggest that the PDGFβ receptor-targeted 
constructs not only exert therapeutic effects in liver fibrosis 
(24, 106, 133) but also in other diseases associated with high 
PDGFβ receptor expression, such as kidney fibrosis (135) and 
some types of cancer (138, 143).
Conclusion
The ever increasing knowledge on molecular mechanisms and 
mediators that orchestrate the progression of liver fibrosis 
can be used to design new therapeutic compounds against 
this lethal disease. The fundamental processes that underlie 
this disease are similar in many other fibrotic and sclerotic 
diseases, including stromal cancers, which broadens the scope 
of applications of such novel compounds. In the past decades, 
the key cells and key mediators that stimulate and inhibit liver 
fibrogenesis have been identified and we used this knowledge 
to create a cell-specific chimeric compound which combines 
the best of two important mediators: the high disease-induced 
receptor expression of one mediator (PDGFR) is used to deliver 
another mediator (IFNγ), endowed with antifibrotic activities, 
to the HSC, yielding Fibroferon. Further studies on the intracel-
lular trafficking of this compound that induces the activation 
of the IFNγ-signaling cascade via binding to the PDGFR are 
in progress. This chimeric molecule might be one of the next-
generation antifibrotic therapeutics. These studies also illustrate 
the surprising adaptability of biological compounds that are the 
natural inhibitors of this chronic disease.
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